This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/chebi/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/pdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/kegg-compound/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/bindingdb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB02659/identifier/drugbank/

Statements

Subject Item
n2:DB02659
rdf:type
n3:Drug
n3:description
A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. [PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single enzyme defects, and for peroxisomal disorders (such as Zellweger syndrome).
n3:group
approved
owl:sameAs
n7:DB02659 n17:DB02659
dcterms:title
Cholic Acid
adms:identifier
n9:221493 n10:46507063 n11:C00695 n12:CHD n13:192176 n14:DB02659 n15:21680 n16:16359
n3:IUPAC-Name
n4:271B4C25-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4C2B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4C2A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4C27-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4C28-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4C29-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4C23-363D-11E5-9242-09173F13E4C5 n4:271B4C3B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4C3D-363D-11E5-9242-09173F13E4C5 n4:271B4C21-363D-11E5-9242-09173F13E4C5 n4:271B4C24-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4C3E-363D-11E5-9242-09173F13E4C5 n4:271B4C22-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B4C3F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4C31-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C32-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4C2C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4C2D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C2F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4C2E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C30-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
81-25-4
n3:Bioavailability
n4:271B4C37-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C39-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C3A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C3C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C36-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C35-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C38-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4C26-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C33-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C34-363D-11E5-9242-09173F13E4C5